Community Bank & Trust Waco Texas lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 9.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,320 shares of the medical research company’s stock after selling 144 shares during the period. Community Bank & Trust Waco Texas’ holdings in Thermo Fisher Scientific were worth $701,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Monument Group Wealth Advisors LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $425,000. Marks Group Wealth Management Inc increased its holdings in Thermo Fisher Scientific by 6.0% in the fourth quarter. Marks Group Wealth Management Inc now owns 8,857 shares of the medical research company’s stock worth $4,701,000 after buying an additional 504 shares during the last quarter. National Wealth Management Group LLC bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at $238,000. Larson Financial Group LLC lifted its position in Thermo Fisher Scientific by 21.1% during the 4th quarter. Larson Financial Group LLC now owns 5,025 shares of the medical research company’s stock valued at $2,667,000 after purchasing an additional 875 shares during the period. Finally, 1900 Wealth Management LLC boosted its stake in Thermo Fisher Scientific by 3.2% in the fourth quarter. 1900 Wealth Management LLC now owns 1,294 shares of the medical research company’s stock valued at $687,000 after acquiring an additional 40 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.
Thermo Fisher Scientific Trading Down 0.5 %
NYSE:TMO traded down $2.60 during mid-day trading on Wednesday, hitting $571.99. 817,016 shares of the company’s stock were exchanged, compared to its average volume of 1,552,031. The firm has a market capitalization of $218.33 billion, a P/E ratio of 37.22, a PEG ratio of 2.31 and a beta of 0.80. The company has a 50 day simple moving average of $572.03 and a 200-day simple moving average of $528.72. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82.
Thermo Fisher Scientific Increases Dividend
The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio is 10.10%.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on TMO. Barclays cut shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. HSBC lifted their target price on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Citigroup began coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective for the company. Finally, Raymond James upped their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Five research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $604.69.
View Our Latest Stock Analysis on Thermo Fisher Scientific
Insider Transactions at Thermo Fisher Scientific
In related news, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the transaction, the director now directly owns 1,207 shares of the company’s stock, valued at $660,192.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock valued at $28,513,384 in the last quarter. 0.32% of the stock is currently owned by company insiders.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Further Reading
- Five stocks we like better than Thermo Fisher Scientific
- Earnings Per Share Calculator: How to Calculate EPS
- High-Yield Texas Instruments Could Hit New Highs Soon
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Stock Market Sectors: What Are They and How Many Are There?
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.